📰 Twist Bioscience News
Page 39 - Twist Bioscience News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Twist Bioscience. Real-time updates on events, politics, business and more.
May 28, 2021
Twist Bioscience Corporation has launched the Twist Library Preparation Enzymatic Fragmentation Kit 2.0, a robust all-in-one solution designed to maximize accuracy and efficiency in library construction and amplification when conducting next-generation sequencing (NGS).
May 26, 2021
They're well below peak levels set earlier this year. But they could be huge winners over the long run.
May 25, 2021
EQS Group-Ad-hoc: Reinet Investments SCA / Key word(s): Annual Results CONSOLIDATED AUDITED FINANCIAL RESULTS FOR THE YEAR ENDED 31 MARCH 2021 AND PROPOSED DIVIDEND 25-May-2021 / 07:31 CET/CEST Release
May 24, 2021
The Factors such as a wide range of applications of synthetic biology, the rising R&D funding and growing initiatives in synthetic biology, declining cost of DNA sequencing and synthesizing, and increasing investments in the market are propelling the growth of this market. However, biosafety, biosecurity, and ethical concerns related to synthetic biology would hamper the growth of this market. The oligonucleotides and synthetic DNA segment accounted for the largest share of the tool segment in ...
May 19, 2021
Twist Bioscience’s Dr. Emily LeProust Disrupting the Future of Bioscience May 19, 2021 Female entrepreneurs are disrupting the traditionally male-dominated field of bioscience. One such disruptor is Dr. Emily Leproust, CEO and co-founder of Twist Bioscience (TWST), whose pioneering work on DNA-based applications and high-throughput DNA synthesis and sequencing is being used in everything from the fight against COVID-19 to brewing a better bottle of beer. “High-throughput DNA sequencing”...
May 12, 2021
E-Mail NEW YORK, May 12, 2021 -- A new Computer Aided Design (CAD) platform for whole genome design is being launched by two pioneers in the world of biotech: Genome Project-write (GP-write) and Twist Bioscience (NASDAQ: TWST). The technology is expected to open up new frontiers in genome research with real world applications to advance development of therapeutics and solutions for environmental health. The CAD technology will be an important development along the path to more facile writin...
May 12, 2021
CAD Platform Developed by GP-Write and Twist to Launch Large Genome Projects May 12, 2021 Share A new Computer Aided Design (CAD) platform for whole genome design is being launched by Genome Project-write (GP-write) and Twist Bioscience. The technology is expected to open up new frontiers in genome research with real-world applications to advance the development of therapeutics and solutions for environmental health. The CAD technology will be an important development along the path to more fac...
May 11, 2021
(Pixabay/Pexels) (Bloomberg) â Cathie Woodâs Ark Innovation ETF plunged to a six-month low, with all but five of its 58 holdings retreating in a broad tech selloff. The ARKK exchange-traded fund that makes concentrated bets on tech companies aiming to disrupt industries fell 5.2% Monday, double the loss in the Nasdaq 100 Index. Itâs now down more than 30% from its February peak. Hardest hit in the portfolio listed in the fundâs May 7 holdings disclosure were two...
May 8, 2021
Author Bio Keith began writing for the Fool in 2012 and focuses primarily on healthcare investing topics. His background includes serving in management and consulting for the healthcare technology, health insurance, medical device, and pharmacy benefits management industries. Follow @keithspeights Twist Bioscience (NASDAQ:TWST) ranks as one of ARK Invest CEO Cathie Woods favorite genomics stocks right now. In this Motley Fool Live video recorded on April 21, 2021, Mot...
May 8, 2021
Welcome to Twist Bioscience Fiscal 2021 Second Quarter Financial Results Conference Call. [Operator Instructions] I would now like to turn the conference call over to Jim Thorburn, Chief Financial Officer. Jim Thorburn -- Chief Financial Officer Thank you, operator. Good afternoon, everyone. Id like to thank all of you for joining us today for Twist Bioscience conference call to review our fiscal 2021 second quarter financial results and business progress. We did issue our financial results ea...